Trending Down-0.0200 (-1.2121%)
  • Bid / Lots
    1.5900/ 3
  • Ask / Lots
    1.6600/ 1
  • Open / Previous Close
    1.6600 / 1.6500
  • Day Range
    Low 1.5626
    High 1.6799
  • 52 Week Range
    Low 0.5171
    High 3.3197
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 1.65
09:32 ET20631.67
09:36 ET11501.66
09:41 ET2501.65
09:52 ET5001.6153
09:57 ET24171.6755
10:06 ET1001.6783
10:10 ET10001.67
10:14 ET85001.6653
10:24 ET82121.66
10:26 ET10001.6401
10:33 ET3001.6401
10:35 ET27291.65
10:37 ET10921.65
10:42 ET34041.65
10:46 ET1001.63
10:53 ET50001.65
10:57 ET1001.65
11:06 ET7001.65
11:09 ET3001.6489
11:15 ET1001.64
11:24 ET18911.63
11:29 ET20001.63
11:40 ET1001.64
11:42 ET4001.64
11:45 ET1061.64
11:51 ET1001.645
11:58 ET20001.64
12:07 ET1001.64
12:34 ET2831.63
12:36 ET3171.63
12:39 ET75611.63
12:43 ET1001.61
01:08 ET8001.6213
01:19 ET10001.62
01:21 ET30001.6399
01:26 ET21031.5626
01:28 ET80001.5701
01:39 ET6001.585
01:42 ET27001.58
01:51 ET7401.58
01:53 ET308981.58
02:15 ET2001.61
02:24 ET10001.6284
02:29 ET2001.63
02:45 ET6001.62
02:56 ET2001.62
03:03 ET5401.615
03:50 ET10251.6118
03:59 ET4061.63
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesNCNA
NuCana PLC
United StatesANEB
Anebulo Pharmaceuticals Inc
United StatesANVS
Annovis Bio Inc
United StatesPYXS
Pyxis Oncology Inc
United StatesMGTA
Magenta Therapeutics Inc
United StatesKNWN
Know Labs Inc
As of 2022-08-15

Company Information

NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatments for cancer patients using its ProTide technology. ProTide are designed to overcome cancer resistance mechanism and generate anti-cancer metabolites in cancer cells. The Company's pipeline includes Acelari, NUC-3373, and NUC-7738. Its ProTide candidates Acelari and NUC-3373 are chemical entities derived from the nucleotide analog and 5- fluorouracil, which are used as chemotherapy agents for the treatment of cancer. Acelari is in a Phase III study for patients with biliary tract cancer. NUC-3373 is in Phase I study for the treatment of a range of patients with solid tumors and a Phase I b study for patient with metastatic colorectal cancer. Its third ProTide candidate, NUC-7738, is a nucleotide analog (3’-deoxyadenosine) and is in Phase I study for patients with solid tumors.

Contact Information

Lochside House, 3 Lochside WayEDINBURGH, United Kingdom EH12 9DT


Non-Executive Independent Chairman of the Board
Andrew Kay
Chief Executive Officer, Co-Founder, Executive Director
Hugh Griffith
Chief Financial Officer
Donald Munoz
Chief Medical Officer
Jeffrey Bloss
Head - Translational Studies
David Harrison

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.